Effect of tadalafil on pulmonary hypoplasia in congenital diaphragmatic hernia of rat fetuses

Background. Pulmonary hypoplasia and persistent pulmonary hypertension in congenital diaphragmatic hernia are the cause of adverse perinatal outcomes. Dissatisfaction with the outcomes of intrauterine surgical correction of CDH determines the search for alternative non-surgical prenatal methods of treating pulmonary hypoplasia in CDH. Objective. To study the effect of a reversible selective inhibitor of specific phosphodiesterase type 5 (tadalafil) on the development of fetal lungs in rats in a model of congenital diaphragmatic hernia. Design and methods. An experimental study was conducted on the possibility of correcting fetal lung hypoplasia in rats when modeling a diaphragmatic hernia with nitrophen (100 mg orally, once on the 9th day of pregnancy). Results. Congenital diaphragmatic hernia was recorded in 12.5 % of offspring. Subcutaneous administration of tadalafil to pregnant rats (0,83 mg/kg, for 10 days, from the 9th day of pregnancy) in the lungs of fetuses increases the number of alveoli (by 22 % at p ≤ 0.05), the area of microvasculature vessels and the volume of lung parenchyma increases (by 1.25 % and 1.13 % more (at p ≤ 0.05)). Conclusion. The results obtained from the first experiment conducted in the Russian Federation to study the effect of tadalafil on the lungs in congenital diaphragmatic hernia of the fetus are comparable with the data of the authors who used sildenafil, however, the use of tadalafil seems more optimal due to the ease of its administration for potential practical use.

1. Chandrasekharan PK, Rawat M, Madappa R, et al. Congenital Diaphragmatic hernia — a review. Maternal health, neonatology and perinatology. 2017: 11:3:6. DOI:10.1186/s40748-017-0045-1.

2. Deprest JA, Benachi A, Gratacos E, et al. Randomized Trial of Fetal Surgery for Moderate Left Diaphragmatic Hernia. PLJ N Engl J Med. 2021: 385:2: 119–129. DOI: 10.1056/NEJMoa2026983.

3. De Bie FR, Basurto D, Kumar S, et al. Sildenafil during the 2nd and 3rd Trimester of Pregnancy: Trials and Tribulations. International journal of environmental research and public health. 2022: 19:18: 11207. DOI:10.3390/ijerph191811207.

4. Okolo F, Zhang G, Rhodes J, et al. Intra- Amniotic Sildenafil Treatment Promotes Lung Growth and Attenuates Vascular Remodeling in an Experimental Model of Congenital Diaphragmatic Hernia. Fetal diagnosis and therapy. 2020: 47:11: 787–799. DOI:10.1159/000508986.

5. Montalva L, Antounians L, Zani A. Pulmonary hypertension secondary to congenital diaphragmatichernia: factors and pathways involved in pulmonary vascular remodeling. Pediatr Res. 2019: 85: 754–768. DOI: 10.1038/s41390-019-0345-4.

6. Magawa S, Nii M, Tanaka H, et al. Phase-1 clinical study of tadalafil administered for selective fetal growth restriction in twin pregnancy. The journal of maternal-fetal & neonatal medicine. 2021: 34:7: 1075–1082. DOI:10.1080/14767058.2019.1624717.

7. Furuhashi F, Tanaka H, Maki S, et al. Tadalafil treatment for preeclampsia (medication in preeclampsia; MIE): a multicenter phase II clinical trial. The journal of maternal-fetal & neonatal medicine. 2021: 34:22: 3709–3715. DOI:10.1080/14767058.2019.1690447.

8. enbrinck R, Tibboel D, Gaillard JL, et al. Experimentally induced congenital diaphragmatic hernia in rats. Journal of pediatric surgery. 1999: 25:4: 426–429. DOI: 10.1016/0022-3468(90)90386-n.

9. Kubo M, Tanaka H, Maki S, et al. Safety and dose-finding trial of tadalafil administered for fetal growth restriction: A phase-1 clinical study. The journal of obstetrics and gynaecology research. 2017: 43:7: 1159–1168. DOI:10.1111/jog.13345.

10. Кluth D, Kangah R, Reich P, et al. Nitrofen- induced diaphragmatic hernias in rats: an animal model. J Pediatr Surg. 1990: 25:8: 850–854. DOI: 10.1016/0022-3468(90)90190-k.

11. Lemus-Varela M de L, Soliz A, et al. Antenatal use of bosentan and/or sildenafil attenuates pulmonary features in rats with congenital diaphragmatic hernia. World journal of pediatrics: WJP. 2014: 10:4: 354–359. DOI: 10.1007/s12519-014-0512-y.

12. Kardon G, Ackerman KG, McCulley DJ, et al. Congenital diaphragmatic hernias: from genes to mechanisms to therapies. Disease models & mechanisms. 2017: 10:8: 955–970. DOI: 10.1242/dmm.028365.

13. Samangaya RA, Mires G, Shennan A, et al. A randomised, double-blinded, placebo-controlled study of the phosphodiesterase type 5 inhibitor sildenafil for the treatment of preeclampsia. Hypertension in pregnancy. 2009: 28:4: 369–382. DOI: 10.3109/10641950802601278.

14. Costlow RD, Manson JM. The heart and diaphragm: target organs in the neonatal death induced by nitrofen (2,4-dichlorophenyl-p-nitrophenyl ether). Toxicology. 1981: 20:2–3: 209–227. DOI: 10.1016/0300-483x(81)90052-4.

15. Migliazza L, Otten C, Xia H, et al. Cardiovascular malformations in congenital diaphragmatic hernia: Human and experimental studies. Journal of pediatric surgery. 1999: 34:9: 1352–1358. DOI: 10.1016/s0022-3468(99)90010-6.